Delivery Order SPE2DB20D3304-SPE2DB25FW8F6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Telmisartan-Amlodipine 40-5 mg tablets (30-count) with a ceiling value of $1,234.32 and an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- On July 28, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $3,078.79 to AmerisourceBergen Drug Corp for the supply of Telmisartan-Amlodipine 80-5 mg tablets (30-count). This firm fixed-price delivery order is non-competitive and carries an ultimate completion date of July 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Telmisartan-HCZ 80-25 mg tablets (unit dose, 30-count packages) valued at $3,031.71. This non-set-aside, competitively awarded delivery order, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a firm fixed-price pharmaceutical supply transaction supporting federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Telmisartan 40 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $3,555.12. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999.99 billion and extending through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $14,672.56 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count). The contract is structured as a firm fixed price delivery order with a completion date of July 25, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this competitively awarded contract. This delivery...
- This is a $1,360.74 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Telmisartan-Amlodipine 40-5 mg tablets, a cardiovascular medication, with a period of performance through January 2, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $3,007.04 to AmerisourceBergen Drug Corp for Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packages of 30 units. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30-count) with a ceiling value of $5,768.16. This delivery order represents a firm fixed price contract with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for completion on August 6, 2025, and will be performed at AmerisourceBergen's corporate office location in...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Telmisartan-Amlodipine 40-5 mg tablets. The $2,774.37 Firm Fixed Price delivery order contract has an ultimate completion date of September 11, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which serves as the primary...
- The Defense Logistics Agency awarded a delivery order valued at $2,833.03 to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count) on August 1, 2025, with an ultimate completion date of August 4, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- SPE2DB20D3304Indefinite Delivery Contract
- SPE2DB20D3304-SPE2DB25FW8F6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Telmisartan-Amlodipine 40-5 mg tablets (30-count) with a ceiling value of $1,101.71. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's ongoing pharmaceutical supply relationship with DLA and is not designated as a set-aside contract. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 29, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen fulfills critical medical supply needs for military and veteran healthcare systems, including the Defense Health Agency and U.S. Coast Guard, delivering a comprehensive range of brand-name and generic medications across multiple therapeutic domains. The company's substantial IDC enables flexible fulfillment of federal medical procurement requirements while supporting DLA's broader pharmaceutical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/28/25 |